2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Stearoyl-CoA Desaturase (SCD)
  5. Stearoyl-CoA Desaturase (SCD) Inhibitor

Stearoyl-CoA Desaturase (SCD) Inhibitor

Stearoyl-CoA Desaturase (SCD) Inhibitors (31):

Cat. No. Product Name Effect Purity
  • HY-50709
    A939572
    		Inhibitor 99.98%
    A939572 is a potent, and orally bioavailable stearoyl-CoA desaturase1 (SCD1) inhibitor with IC50 values of <4 nM and 37 nM for mSCD1 and hSCD1, respectively.
  • HY-15823
    CAY10566
    		Inhibitor 99.82%
    CAY10566 is a potent, orally bioavailable and selective stearoyl-CoA desaturase1 (SCD1) inhibitor with IC50s of 4.5 and 26 nM in mouse and human enzymatic assays, respectively. CAY10566 also shows excellent cellular activity in blocking the conversion of saturated long-chain fatty acid-CoAs (LCFA-CoAs) to monounsaturated LCFA-CoAs in HepG2 cells (IC50=7.9 nM or 6.8 nM).
  • HY-13070
    MK-8245
    		Inhibitor 99.04%
    MK-8245 is a potent, liver-targeted stearoyl-CoA desaturase (SCD) inhibitor, with IC50s of 1 nM for human SCD1 and 3 nM for both rat SCD1 and mouse SCD1, with antidiabetic and antidyslipidemic efficacy.
  • HY-15822
    MF-438
    		Inhibitor 99.92%
    MF-438 is a potent and orally bioavailable stearoyl-CoA desaturase 1 (SCD1) inhibitor with an IC50 of 2.3 nM for rSCD1.
  • HY-111315
    XEN103
    		Inhibitor
    XEN103 is a SCD1 inhibitor, with IC50s of 14 nM and 12 nM for mSCD1 and SCD1 in HepG2 cell. XEN103 can be used for research of obesity and type 2 diabetes. XEN103 also induces sebaceous gland atrophy in mice.
  • HY-114527
    TPMP-I-2
    		Inhibitor
    TPMP-I-2 is an anticancer agent that induces cancer cell lines Apoptosis and decreases protein levels of stearoyl-CoA desaturase. TPMP-I-2 prolongs the survival time of nude rats in a simulated micrometastatic cervical cancer model and reduces tumor growth in a breast cancer model in nude mice combined with immunotoxins.
  • HY-155209
    SCD1 inhibitor-5
    		Inhibitor
    SCD1 inhibitor-5 (compound 51) is a SCD1 inhibitor,with the IC50 values​ of 0.13 μM and 31 μM for H2122 and H1819, respectively. SCD1 inhibitor-5 can be used in cancer research.
  • HY-15700
    PluriSIn 1
    		Inhibitor 99.84%
    PluriSIn 1 (NSC 14613) is an inhibitor of stearoyl-coA desaturase (SCD), and is a pluripotent cell-specific inhibitor.
  • HY-12756A
    E6446 dihydrochloride
    		Inhibitor 99.96%
    E6446 dihydrochloride is a potent and orally acitve TLR7 and TLR9 antagonist, used in the research of deleterious inflammatory responses. E6446 dihydrochloride is also a potent SCD1 inhibitor (KD: 4.61 μM), significantly inhibiting adipogenic differentiation and hepatic lipogenesis through SCD1-ATF3 signaling. E6446 dihydrochloride also improves liver pathology in high-fat diet (HFD)-fed mice and may be useful in the study of non-alcoholic fatty liver disease (NAFLD).
  • HY-124751
    YTX-465
    		Inhibitor 99.06%
    YTX-465 is a stearoyl-CoA desaturase (Ole1/SCD) inhibitor. YTX-465 inhibits Ole1 and SCD1 with IC50s of 0.039 μM and 30.4 μM, respectively. YTX-465 can be used in the research of Parkinson’s disease and other synucleinopathies.
  • HY-19762
    GSK1940029
    		Inhibitor 99.82%
    GSK1940029 (SCD inhibitor 1) is a stearoyl-coa desaturase (SCD) inhibitor extracted from patent WO/2009060053 A1, compound example 16.
  • HY-N6807
    Elemicin
    		Inhibitor 99.22%
    Elemicin is an orally active alkenylbenzene widely distributed in many herbs and spices. Elemicin inhibits Stearoyl-CoA Desaturase 1 (SCD1) by metabolic activation. Elemicin has anti-influenza activities, antimicrobial, antioxidant, and antiviral activities. Elemicin and its reactive metabolite of 1′-Hydroxyelemicin can induce hepatotoxicity.
  • HY-100249
    XEN723
    		Inhibitor 99.90%
    XEN723 is a novel and potent thiazolylimidazolidinone inhibitor of Stearoyl-CoA Desaturase (SCD1) with IC50s of 45 and 524 nM in mouse and HepG2 cell, respectively.
  • HY-127143
    Sterculic acid
    		Inhibitor ≥99.0%
    Sterculic acid is a stearoyl-CoA desaturase-1 (SCD1) inhibitor. Sterculic acid specifically inhibits the delta-9 desaturase (Δ9D) activity with an IC50 value of 0.9 μM.
  • HY-141525
    SCD1 inhibitor-4
    		Inhibitor 98.93%
    SCD1 inhibitor-4 is a potent, orally active stearoylCoA desaturase-1 (SCD1) inhibitor. SCD1 inhibitor-4 can be used for the research of diabetes.
  • HY-11034
    CVT-12012
    		Inhibitor 99.16%
    CVT-12012 is a potent and orally bioavailable stearoyl-coA desaturase (SCD) inhibitor, with IC50s of 38 nM, 6.1 nM for rat microsomal and human HEPG2, respectively.
  • HY-113638
    CVT-11127
    		Inhibitor 99.88%
    CVT-11127 is a potent SCD inhibitor. CVT-11127 induces apoposis and arrests the cell cycle at the G1/S phase. CVT-11127 has the potential for the research of lung cancer.
  • HY-155033
    SSI-4
    		Inhibitor 99.95%
    SSI-4 is an inhibitor of Stearoyl CoA desaturase 1 (SCD1) , which can be modified with 11C, used as a ligand to in vivo small animal PET/CT imaging of SCD1.
  • HY-12756
    E6446
    		Inhibitor ≥98.0%
    E6446 is a potent and orally acitve TLR7 and TLR9 antagonist, used in the research of deleterious inflammatory responses. E6446 is also a potent SCD1 inhibitor (KD: 4.61 μM), significantly inhibiting adipogenic differentiation and hepatic lipogenesis through SCD1-ATF3 signaling. E6446 also improves liver pathology in high-fat diet (HFD)-fed mice and may be useful in the study of non-alcoholic fatty liver disease (NAFLD).
  • HY-139077
    SCD1 inhibitor-3
    		Inhibitor 98.55%
    SCD1 inhibitor-3 is a safe, potent and orally active SCD1 inhibitor. SCD1 inhibitor-3 can be used for the research of metabolic diseases such as obesity, type II diabetes and dyslipidemia, as well as skin diseases, acne and cancer.